Oxygen Of The Saccharide Radical Bonded Directly To A Cyclohexyl Ring Patents (Class 514/35)
- The nitrogen atoms are in N-C(=N)-N groups (e.g., streptomycin, etc.) (Class 514/37)
- Two saccharide radicals bonded through only oxygen to adjacent ring carbons of the cyclohexyl ring (Class 514/38)
- Two saccharide radicals bonded through only oxygen to 4- and 6- positions of the cyclohexyl ring (Class 514/40)
-
Patent number: 5962515Abstract: Process for isolation of 1-(3,4-methylenedioxy-phenyl)-1E-tetradecene from Piper longum. Processes for synthesis of 1-(3,4-methylenedioxy-phenyl)-1E-tetradecene; its stereoisomers and analogues are disclosed. The compounds isolated and synthesized according to this invention have immunomodulatory properties and can be used to treat tumors and infections.Type: GrantFiled: May 29, 1997Date of Patent: October 5, 1999Assignee: National Institute of ImmunologyInventors: Shakti N. Upadhyay, Ram A. Vishwakarma, Sabari Ghosal, Supriya Shukla, Chanda Bose, Anita Kamra
-
Patent number: 5929113Abstract: This invention provides a method for repelling biting insects such as mosquitoes, ticks, and biting flies by topically applying to the skin of a subject emu oil, fractions of emu oil obtained by flash chromatography or a composition comprising emu oil or active fractions thereof and at least one other insect repellent such as citronella, DEET or saponin. Also provided are compositions for repelling biting insects comprising diluted fractions of emu oil, and compositions comprising emu oil or active fractions thereof and at least one other insect repellent such as citronella, DEET or saponin.Type: GrantFiled: June 16, 1997Date of Patent: July 27, 1999Assignee: AgraQuest, Inc.Inventors: Denise C. Manker, Pamela Gail Marrone, Stephen Judd
-
Patent number: 5925622Abstract: An aryl glucuronide of 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide, preferably an O-aryl glucuronide, as well as methods for the convenient synthesis of these aryl glucuronides, highly stable and low toxicity pharmaceutical composition containing these aryl glucuronides, and methods for use of these pharmaceutical compositions, for example, for treatment of inflammation, infections, etc.Type: GrantFiled: July 13, 1998Date of Patent: July 20, 1999Assignee: Romark Laboratories, L.C.Inventors: Jean-Fran.cedilla.ois Rossignol, Marc S. Ayers
-
Patent number: 5900406Abstract: The invention described herein provides for methods of screening for compounds that can be used to prevent or inhibit the growth of microbial eukaryotes, particularly plant or animal pathogens. The screening methods of the invention involve the step of screening compounds for the ability to inhibit Group I intron I splicing. In addition, to directly screening for compounds that inhibit Group I intron splicing, the screening methods of the invention include screening for compounds that bind to prokaryotic 16S ribosomal RNA because of the correlation, described herein, between group I intron inhibition and binding to prokaryotic 16S ribosomal RNA. The range of possible compounds for screening by the screening methods of the invention is preferably limited to 2-deoxystreptamine derivatives.Another aspect of the invention is to provide methods of treating or preventing infections with eukaryotic microbes by administering an effective amount of a compound that inhibits group I intron splicing.Type: GrantFiled: June 8, 1994Date of Patent: May 4, 1999Assignee: NZYM, Inc.Inventors: Uwe von Ahsen, Julian E. Davies, Renee Schroeder
-
Patent number: 5872104Abstract: Disclosed are novel methods, combinations of agents and kits for use in killing, or inhibiting the growth of, microorganisms. Enhanced antimicrobial action is provided by using a methylation inhibitor, as exemplified by using an agent that inhibits methylation or maturation of bacterial RNA in combination with, e.g., a macrolide lincosamide streptogramin B (MLS) antibiotic. The methods and compositions described may be employed to reduce the resistance of susceptible microorganisms to antimicrobial agents and thus to treat animals or patients with infections.Type: GrantFiled: December 27, 1994Date of Patent: February 16, 1999Assignee: Oridigm CorporationInventors: Nicolaas M. J. Vermeulen, Dennis E. Schwartz
-
Patent number: 5795874Abstract: The compound of the formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are as defined herein, are described. These compounds are antibacterial agents.Type: GrantFiled: December 20, 1996Date of Patent: August 18, 1998Assignee: Schering CorporationInventors: Viyyoor M. Girijavallabhan, Anil K. Saksena, Frank Bennett, Edwin Jao, Naginbhai M. Patel, Ashit Ganguly
-
Patent number: 5776891Abstract: The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.Type: GrantFiled: June 7, 1995Date of Patent: July 7, 1998Assignee: Rush Prebyterian-St. Luke Medical CenterInventors: John S. Coon, Mannarsamy Balasubramanian, R. Martin Emanuele, Himanshu Shah
-
Patent number: 5770585Abstract: This invention is directed to a homogenous water-in-perfluorochemical stable liquid dispersion for acceptable therapeutic administration of a drug to the lung of an animal. The dispersion includes a perfluorochemical liquid, water, surfactant and drug, wherein the water is homogeneously dispersed in the perfluorochemical to form a stable water-in-perfluorochemical liquid dispersion. The perfluorochemical constitutes greater than 50% by volume of the dispersion, and the drug is contained in the dispersion in an effective therapeutic amount.The invention further includes a method of delivering a drug to the lung of an animal. This aspect of the invention includes administering a stable homogenous water-in-perfluorochemical liquid dispersion to the animal lung or a section thereof. If desired, the method may further include delivering a breathable gas to the lung with a mechanical ventilator during the administration.Type: GrantFiled: May 8, 1995Date of Patent: June 23, 1998Inventors: Robert J. Kaufman, Thomas J. Richard, Richard A. Stephens, Thomas H. Goodin, John S. Allen, Tony E. Layton
-
Patent number: 5739118Abstract: Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a genetic vaccine facilitator and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produce a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.Type: GrantFiled: April 1, 1994Date of Patent: April 14, 1998Assignees: Apollon, Inc., The Trustees of the University of PennsylvaniaInventors: Richard A. Carrano, Bin Wang, David B. Weiner
-
Patent number: 5736523Abstract: This invention relates to a naphthoquinone derivatives, to processes and to intermediates for preparing these derivatives, to pharmaceutical composition and to the use of these derivatives as antitumor agents in mammals.Type: GrantFiled: March 10, 1995Date of Patent: April 7, 1998Assignee: Biochem Pharma Inc.Inventors: Giorgio Attardo, Tibor Breining, Marc Courchesne, Serge Lamothe, Jean-Fran.cedilla.ois Lavallee, Dieu Nguyen, Rabindra Rej, Yves St-Denis, Wuyi Wang, Yao-Chang Xu, France Barbeau, Elaine Lebeau, Jean Louis Kraus
-
Patent number: 5681812Abstract: The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.Type: GrantFiled: May 19, 1995Date of Patent: October 28, 1997Assignee: Rush Presbyterian-St. Luke's Medical CenterInventors: John S. Coon, Mannarsamy Balasubramanian, R. Martin Emanuele, Himanshu Shah
-
Patent number: 5677288Abstract: A method is disclosed for reducing excitotoxic damage to neurons, which can occur as a result of stroke, cardiac arrest, or other events or conditions. This method involves administering an aminoglycoside that suppresses the flow of calcium ions into neurons through N-type calcium channels. To be effective for such use, an aminoglycoside must suppress N-channel activity at a potency greater than streptomycin. Aminoglycosides which meet this criterion (which includes neomycin and Gentamicin) can suppress the depolarizing activation of neurons, which in turn controls the release of glutamate, a neurotransmitter that becomes an endogenous toxin under excitotoxic conditions. Numerous aminoglycosides were tested in in vitro screening tests using brain cell membrane fragments to evaluate N-channel blocking potency.Type: GrantFiled: April 15, 1994Date of Patent: October 14, 1997Assignee: Cypros Pharmaceutical CorporationInventor: Paul J. Marangos
-
Patent number: 5677285Abstract: Provided are new derivatives of neuraminic acid of formula (I), where Ac represents an acyl residue of an aliphatic, araliphatic, aromatic, alicyclic, or heterocyclic carboxylic acid, including carboxylic amides, their 2-hydrocarbyl-glycosides, and their peracylated derivatives at the hydroxy groups of both these series of amides. These compositions are therapeutically useful in providing a protective effect against the neurotoxicity induced by excitatory amino acids, and can therefore be used in therapies of the central nervous system.Type: GrantFiled: April 26, 1995Date of Patent: October 14, 1997Assignee: Fidia S.P.A.Inventors: Aurelio Romeo, Gunter Kirschner, Hari Manev, Martino Trimarco, Gino Toffano
-
Composition for protecting and/or combating blemishes on and/or ageing of the skin, and uses thereof
Patent number: 5670487Abstract: The invention relates to a composition for combating skin blemishes and/or for combating ageing of the skin, as well as for protecting the skin, particularly against ultraviolet rays. The composition contains arbutin and at least one ultraviolet screening agent chosen from the group consisting of benzylidenecamphor and derivatives thereof, in a cosmetically and/or dermatologically acceptable medium.Type: GrantFiled: June 20, 1996Date of Patent: September 23, 1997Assignee: L'OrealInventors: Jean-Francois Grollier, Herve Cantin, Didier Gagnebien -
Patent number: 5652221Abstract: A synthetic insulin mimetic compound is disclosed. Small synthetic amines of disaccharides, such as 2-deoxy-2-amino-galactopyranosyl pinitol are shown to mimic the action of insulin and to modulate its action.Type: GrantFiled: November 7, 1994Date of Patent: July 29, 1997Assignee: The University of Virginia Patent FoundationInventors: Joseph Larner, John Price, Thomas Picariello, Laura Huang
-
Patent number: 5650398Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.Type: GrantFiled: June 2, 1995Date of Patent: July 22, 1997Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani, Joanne Recchia
-
Patent number: 5622938Abstract: Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier having the formula: ##STR1## wherein R is phenyl-(CH.sub.2).sub.10 CO or C.sub.12 H.sub.25 NHCO adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions containing the particles. Pharmaceutical compositions containing the particles exhibit unexpected bioavailability and are useful in methods of treating mammals.Type: GrantFiled: May 19, 1995Date of Patent: April 22, 1997Assignee: Nano Systems L.L.C.Inventor: Sui-Ming Wong
-
Patent number: 5595977Abstract: The present invention relates to novel amino glycoside salts of sucrose-octa-O-sulfonic acid of formula I:([sucrose-octa-O-sulfonic acid.sup.8- ]-[R-(NH.sub.3.sup.+).sub.x ].sub.y -M.sub.z.sup.n+) (I)(x.multidot.y)+(z.multidot.n)=8x.multidot.y.epsilon.N.vertline.[4.ltoreq.x.multidot.y.ltoreq.8], wherein N is the set of natural numbers,x.epsilon.Z.vertline.[4.ltoreq.x.ltoreq.6], wherein Z is the set of integersz.epsilon.N.vertline.[0.ltoreq.z.ltoreq.4],n.epsilon.Z.vertline.[1.ltoreq.n.ltoreq.3],wherein R is a sugar moiety of an amino glycoside and M is a metal ion or an ammonium ion, said compounds being useful for treating ulcerations of the stomach and duodenum.Type: GrantFiled: October 27, 1993Date of Patent: January 21, 1997Assignee: Dumex-Alpharma A/SInventors: Hjarne Dyrsting, Torben Koch
-
Patent number: 5591715Abstract: The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.Type: GrantFiled: June 7, 1995Date of Patent: January 7, 1997Assignee: Rush Presbyterian-St. Luke's Medical CenterInventors: John S. Coon, Mannarsamy Balasubramanian, R. Martin Emanuele, Himanshu Shah
-
Patent number: 5534408Abstract: Disclosed is a method for the inhibition of binding of a ligand to an RNA, the inhibition being mediated by a small organic molecule which binds to the RNA, thereby inhibiting ligand binding. A preferred class of small organic molecules are the 2-deoxystreptamine (2-DOS) aminoglycosides. Disclosed herein are members of the 2-DOS class that are useful for the inhibition of binding of Rev to an RNA containing an RRE. In an HIV infected cell, a consequence of the inhibition of the ability of Rev to bind to the RRE in HIV encoded transcripts is inhibition of HIV replication.Type: GrantFiled: September 24, 1993Date of Patent: July 9, 1996Assignee: University Of Massachusetts Medical CenterInventors: Michael R. Green, Maria L. Zapp, Seth Stern
-
Patent number: 5468747Abstract: Compounds having the formula (I): ##STR1## in which any two of K, L and M are nitrogen and the other is CE; X and Y are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.2-4 alkynyloxy, phenyl, benzyloxy, cyano, isocyano, isothiocyanato, nitro, NR.sup.1 R.sup.2, NR.sup.1 OR.sup.2,N.sub.3, NHCOR.sup.1, NR.sup.1 CO.sub.2 R.sup.2, NHCONR.sup.1 R.sup.2, N.dbd.CHNR.sup.1 R.sup.2, NHSO.sub.2 R.sup.1, OR.sup.1, OCOR.sup.1, OSO.sub.2 R.sup.1, SR.sup.1, SOR.sup.1, SO.sub.2 R.sup.1, SO.sub.2 OR.sup.1, SO.sub.2 NR.sup.1 R.sup.2, COR.sup.1, CR.sup.1 .dbd.NOR.sup.2, CHR.sup.1 CO.sub.2 R.sup.2, CO.sub.2 R.sup.1, CONR.sup.1 R.sup.2, CSNR.sup.1 R.sup.2, CH.sub.3 O.sub.2 C.C:CH.OCH.sub.Type: GrantFiled: December 2, 1994Date of Patent: November 21, 1995Assignee: Zeneca LimitedInventors: John M. Clough, Christopher R. A. Godfrey, Ian T. Streeting, Rex Cheetham
-
Patent number: 5443829Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.Type: GrantFiled: September 24, 1993Date of Patent: August 22, 1995Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
-
Patent number: 5376651Abstract: The present invention relates to the use of 20(R)-22-oxavitamin D analogues for treatment or prevention of skin ageing, and to the use of such compounds for preparation of pharmaceutical compositions for teatment and/or prevention of skin ageing.Type: GrantFiled: January 8, 1993Date of Patent: December 27, 1994Assignee: Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktiesel SKAB)Inventor: Lise Binderup
-
Patent number: 5364843Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are piperazinyl benzyl compounds such as 1-[.alpha.-(4-Chlorophenyl)-3-methoxybenzyl]-4-allylpiperazine dihydrochloride.Type: GrantFiled: June 10, 1992Date of Patent: November 15, 1994Assignee: Burroughs Wellcome Co.Inventor: Ann C. King
-
Patent number: 5346897Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.Type: GrantFiled: June 10, 1992Date of Patent: September 13, 1994Assignee: Burroughs Wellcome Co.Inventor: Ann C. King
-
Patent number: 5326753Abstract: The present invention relates to a freeze-dried preparation comprising (1) about 5 to about 50 W/W% of a non-volatile acid and/or a salt thereof, (2) about 10 to about 95 W/W% of 4-O-(2-deoxy-2-dimethylamino-4,6-O-ethylidene-.beta.-D-glucopyranosyl)-4'- demethyl-4-epipodophyllotoxin hydrochloride and (3) 0 to about 85 W/W% of at least one sugar as a stabilizer.Type: GrantFiled: May 20, 1992Date of Patent: July 5, 1994Assignee: Nippon Kayaku Kabushiki KaishaInventors: Kazuo Ohtsuki, Taka'aki Ohkuma
-
Patent number: 5310730Abstract: A skin treatment composition comprising at least one glycoside of hydroquinone having the general formula: ##STR1## wherein R represents a pentose residue, a hexose residue, an amino sugar residue, or an uronic acid residue, or the methylated product thereof in a skin treatment base. This skin treatment composition can further contain at least one UV absorber. The hydroquinone glycoside (I) exhibits an excellent depigmentation effect and effectively suppresses skin irritation caused by the UV absorber.Type: GrantFiled: April 16, 1987Date of Patent: May 10, 1994Assignee: Shiseido Company Ltd.Inventors: Yoshimori Fujinuma, Tomohisa Asahara, Satoru Akiu, Yumiko Suzuki, Hideyuki Ichikawa, Yoshio Katsumura
-
Patent number: 5273965Abstract: Methods for enhancing the transport of pharmacologically active substances across mucous membranes of an animal by administration of pharmaceutical compositions comprising modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract. Also disclosed are modified saponins having reduced irritability wherein the fatty acid moiety is removed by hydrolysis or the aldehyde group is reduced. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.Type: GrantFiled: July 2, 1992Date of Patent: December 28, 1993Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
-
Patent number: 5254538Abstract: The invention relates to methods for enhancing wound healing; enhancing gastric, duodenal, esophageal, decubitus, genito urinary ulcer and ulcerative keratitis healing; inhibiting scar formation; and treating periodontal disease in an animal by the topical, oral parenteral, transdermal or ophthalmic administration of a vitamin D compound.Type: GrantFiled: January 27, 1992Date of Patent: October 19, 1993Assignee: Trustees of Boston UniversityInventors: Michael F. Holick, Xiao Tian
-
Patent number: 5208238Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are 2-(aminoethylamino) pyridines such as (E)-3-(6-(N-(2-Dimethylaminoethyl)-4-methoxybenzylamino)-2-pyridyl)acrylic acid.Type: GrantFiled: June 10, 1992Date of Patent: May 4, 1993Assignee: Burroughs Wellcome CompanyInventor: Ann C. King
-
Patent number: 5190949Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.Type: GrantFiled: June 10, 1992Date of Patent: March 2, 1993Assignee: Burroughs Wellcome CompanyInventor: Ann C. King
-
Patent number: 5166139Abstract: Complexes of saponins from Centella asiatica, terminalia sp. and Terminalia sericea and relevant aglycons with phospholipids are described. The saponins may be asiaticoside, madecassicoside and sericoside. The molar ratio of phospholipids to saponins is from 0.5 to 2. The phospholipids are selected from the group consisting of soy lecithins, phospholipids from bovine or swine brain or cutis, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine in which the acyl groups can be the same or different and are mostly derived from palmitic, stearic, oleic, linoleic, linolenic acids. Pharmaceutical compositions and the method of treatment are also described.Type: GrantFiled: January 18, 1991Date of Patent: November 24, 1992Assignee: Indena, S.p.A.Inventors: Ezio Bombardelli, Gianfranco Patri, Roberto Pozzi
-
Patent number: 5098899Abstract: A novel and effective treatment of psoriatic arthritis is provided using biologically active forms of vitamin D analogues and metabolites, and preferrably 1,25-dihydroxy vitamin D.sub.3. The administration of vitamin D analogues and metabolites may be made orally, topically, or parenterally. Substitive improvements in both the arthritic condition and skin lesions result after approximately two month's treatment when effective dosages are provided and maintained.Type: GrantFiled: December 14, 1990Date of Patent: March 24, 1992Assignee: Trustees of Boston UniversityInventors: Lawrence Gilbert, Michael F. Holick
-
Patent number: 5066645Abstract: The present invention provides antitumor 4'-Demethylepipodophyllotoxin glycosides characterized by the fact that the glycoside moiety is altrose.Type: GrantFiled: September 1, 1989Date of Patent: November 19, 1991Assignee: Bristol-Myers CompanyInventors: Takeshi Ohnuma, Hideaki Hoshi, Hideo Kamei, Takayuki Naito
-
Patent number: 5057540Abstract: Substantially pure saponins are disclosed. The saponins of the present invention are useful as immune adjuvants. Disclosed as well are immune response-provoking compositions comprising an antigen in admixture with the substantially pure saponins.Type: GrantFiled: August 27, 1990Date of Patent: October 15, 1991Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Dante J. Marciani
-
Patent number: 5037816Abstract: A method of treating psoriasis in a patient which comprises administering to said patient an effective amount of a vitamin D compound which is capable of stimulating the differentiation of cultured tumor cells or normal rodent or human fibroblasts or keratinocytes in vitro.Type: GrantFiled: December 21, 1987Date of Patent: August 6, 1991Assignee: The General Hospital CorporationInventors: Michael F. Holick, Julia McLaughlin
-
Patent number: 4997931Abstract: The present invention relates to novel antitumor compounds which are 4'-demethylepipodophylloxtoxin derivatives. More particularly, the novel compounds are 4'-demethylepipodophyllotoxin allopyranosides, allofuranosides, and mannopyranosides.Type: GrantFiled: June 11, 1990Date of Patent: March 5, 1991Assignee: Bristol-Myers Squibb CompanyInventors: Takeshi Ohnuma, Hideaki Hoshi
-
Patent number: 4958010Abstract: Novel antitumor epipodophyllotoxin glucoside lactam derivatives are prepared by first converting the lactone ring of the parent compound to the open-chain trans-hydroxy hydrazide, condensing the hydrazide with a carbonyl compound to form the corresponding hydrazone, and finally cyclizing the trans-hydroxy hydrazone using diethylazodicarboxylate and triphenylphosphine.Type: GrantFiled: January 30, 1989Date of Patent: September 18, 1990Assignee: Bristol-Myers CompanyInventors: John F. Kadow, Dolatrai M. Vyas
-
Patent number: 4927638Abstract: A solution of etoposide in dimethylisosorbide is disclosed. The solution is useful for filling gelatin capsules and may also be formulated into parenteral dosage forms.Type: GrantFiled: September 12, 1988Date of Patent: May 22, 1990Assignee: Bristol-Myers CompanyInventors: Gururaj Bykadi, Murray A. Kaplan, Richard G. Corrao, Edward J. Bara, Ismat Ullah, Shreeram N. Agharkar
-
Patent number: 4888419Abstract: This invention relates to novel 3'-demethoxy epipodophyllotoxin glucosides, their use as anti-tumor agents, and pharmaceutical compositions thereof.Type: GrantFiled: August 31, 1987Date of Patent: December 19, 1989Assignee: Bristol-Myers CompanyInventors: Mark G. Saulnier, Dolatrai M. Vyas
-
Patent number: 4792545Abstract: Boholmycin antibiotic is prepared by fermentation of Streptomyces hygroscopicus H617-25 (ATCC No. 53240) in a nutrient medium preferably comprising glycerol, bacto-liver, cornsteep liquor, ammonium sulfate, sodium chloride and calcium carbonate. The antibiotic and pharmaceutically acceptable salts and hydrates thereof and compositions containing these are effective against Gram-positive, Gram-negative and acid-fast bacteria and against bacterial strains which are resistant to previously known aminoglycoside antibiotics and are useful to treat bacterial infections in mammals.Type: GrantFiled: January 8, 1986Date of Patent: December 20, 1988Assignee: Bristol-Myers CompanyInventors: Kyoichiro Saitoh, Mitsuaki Tsunakawa, Masataka Konishi, Takeo Miyaki
-
Patent number: 4778785Abstract: A pharmaceutical composition for retarding and reducing cachexia comprising, as an efficacious ingredient, at least one compound selected from the group consisting of benzaldehyde and 4,6-O-benzylidene-D-glucose, and a method for retarding and reducing cachexia in humans which comprises administering to an affected human at least one said compound.Type: GrantFiled: August 29, 1986Date of Patent: October 18, 1988Assignees: Kaken Pharmaceutical Co., Ltd., Rikagaku KenkyushoInventors: Mutsuyuki Kochi, Shinichiro Esumi, Setsuo Takeuchi
-
Patent number: 4764505Abstract: A skin treatment composition comprising at least one glycoside of hydroquinone having the general formula: ##STR1## wherein R represents a pentose residue, a hexose residue, an amino sugar residue, or an uronic acid residue, or the methylated product thereof in a skin treatment base. This skin treatment composition can further contain at least one UV absorber. The hydroquinone glycoside (I) exhibits an excellent depigmentation effect and effectively suppresses skin irritation caused by the UV absorber.Type: GrantFiled: March 20, 1985Date of Patent: August 16, 1988Assignee: Shiseido Company Ltd.Inventors: Yoshimori Fujinuma, Tomohisa Asahara, Satoru Akiu, Yumiko Suzuki, Hideyuki Ichikawa, Yoshio Katsumura
-
Patent number: 4650790Abstract: The invention relates to a synergistic antibiotic composition useful for the treatment of respiratory, gastrointestinal or urinary infections and septicaemia of domestic animals. The composition comprises tiamulin hydrogen fumarate and an aminoglycoside antibiotic or a pharmaceutically acceptable salt thereof in a weight ratio of 5:1 to 1:5. The active components are admixed or diluted with a carrier, used in veterinary therapy, in a weight ratio of 1:1 to 1:50 and formulated for oral or parenteral application.Type: GrantFiled: March 28, 1985Date of Patent: March 17, 1987Assignee: Patentbureau DanubiaInventors: Ferenc Simon, Attila Romvary, Janos Varga, Laszlo Bozzay, Edit Bruckner nee Gabor
-
Patent number: 4554269Abstract: This invention relates to new aminoglycoside derivatives and pharmaceutically acceptable salts thereof. More particularly it relates to new aminoglycoside derivatives and pharmaceutically acceptable salts thereof which have anti-viral activity, and immuno-stimulating activity and pharmaceutical compositions comprising the same. In addition, this invention also relates to methods of preparing the aminoglycoside derivatives and salts thereof.Type: GrantFiled: January 24, 1984Date of Patent: November 19, 1985Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Takao Takaya, Nobuyoshi Yasuda, Hideo Tsutsumi, Keiji Matsuda